Anne Andrei currently serves as a commercial advisor to the Empire Discovery Institute. She has advised on the commercial aspects of drug development programs from academia, foundations and the pharmaceutical industry including the Harrington Discovery Institute (HDI), the Medical University of South Carolina, investors and incubators (BioMotiv, Cincytech; Prof Altius Management) and biotech start-ups (CerSci Therapeutics and Formula Inc.) among others. She strives to identify “value creation” drivers in various therapeutic markets.
Anne started her career in advertising (Backer Spielvogel Bates, South East Asia), then moved to market research with two long-term healthcare awareness campaigns for Unicef in Eastern Europe. On her return to the USA she continued to support international market research projects for healthcare strategy providers, B&N Philadelphia (Pravachol, Excedrin, Cefzil) and SDI Plymouth Meeting (creation and management of a
3-continents-wide influenza tracking network to inform Relenza and Tamiflu supply chains) before moving to large pharmaceutical companies: Global Business intelligence unit at Wyeth (Mylotarg and other projects), and Knowledge Management at AstraZeneca (emerging and mature products).
Later she was recruited by high growth, rare disease biopharmaceutical company, Viropharma, to head the market research department that supported the relaunch of vancomycin oral for c. difficile infections, the commercial positioning and forecasting of Maribavir for CMV post-transplant; and commercial due diligence efforts for business development opportunities. Anne’s last assignment prior establishing herself as an independent consultant, was as Director of Market Research and Business Strategies at Prism Pharmaceuticals, which was acquired by Baxter International in 2011.
Anne believes that mapping market landscapes, even at early R&D stages, is a winning strategy. It helps focus preclinical and clinical plans and creates powerful stories for all stakeholders.